These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 28487979)

  • 1. TRAIL mutant membrane penetrating peptide alike-MuR6-TR enhances the antitumor effects of TRAIL in pancreatic carcinoma both in vitro and in vivo.
    Sun L; Chen C; Zhu A; Huang Y; Zhu H; Yi C
    Int J Mol Med; 2017 Jun; 39(6):1468-1476. PubMed ID: 28487979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
    Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL mutant membrane penetrating peptide alike (TMPPA) TRAIL‑Mu3 enhances the antitumor effects of TRAIL in vitro and in vivo.
    Zhu H; Yan J; Xu Q; Wei L; Huang X; Chen S; Yi C
    Mol Med Rep; 2017 Dec; 16(6):9607-9612. PubMed ID: 29039511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
    Fang F; Wang AP; Yang SF
    Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells.
    Matsuzaki H; Schmied BM; Ulrich A; Standop J; Schneider MB; Batra SK; Picha KS; Pour PM
    Clin Cancer Res; 2001 Feb; 7(2):407-14. PubMed ID: 11234897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model.
    Byeon HJ; Choi SH; Choi JS; Kim TH; Lee ES; Lee KC; Youn YS
    Biomed Pharmacother; 2014 Feb; 68(1):65-9. PubMed ID: 24268811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
    Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
    Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
    Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma.
    Kondo K; Yamasaki S; Inoue N; Sugie T; Teratani N; Kan T; Shimada Y
    Surg Today; 2006; 36(11):966-74. PubMed ID: 17072716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy.
    Yoo JD; Bae SM; Seo J; Jeon IS; Vadevoo SMP; Kim SY; Kim IS; Lee B; Kim S
    Sci Rep; 2020 Nov; 10(1):19997. PubMed ID: 33203916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy.
    Cai Y; Liu X; Huang W; Zhang K; Liu XY
    Acta Biochim Biophys Sin (Shanghai); 2012 Jun; 44(6):535-43. PubMed ID: 22635106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
    Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS
    Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity.
    Kim TH; Jiang HH; Park CW; Youn YS; Lee S; Chen X; Lee KC
    J Control Release; 2011 Feb; 150(1):63-9. PubMed ID: 21062635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.
    Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Jiang X
    Nanotechnology; 2011 Jul; 22(26):265105. PubMed ID: 21586819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
    Zhu K; Fang W; Chen Y; Lin S; Chen X
    Oncol Rep; 2014 Sep; 32(3):1234-42. PubMed ID: 25017445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells.
    Lei J; Wu Z; Jiang Z; Li J; Zong L; Chen X; Duan W; Xu Q; Zhang L; Han L; Ma Q; Wang Z; Zhang D
    Oncotarget; 2016 Dec; 7(50):83601-83610. PubMed ID: 27876704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial.
    Jiang J; Liu X; Deng L; Zhang P; Wang G; Wang S; Liu H; Su Y
    Eur J Pharmacol; 2014 Oct; 740():722-32. PubMed ID: 24929054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.